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Advanced heart failure is a heterogeneous condition uniﬁed by a very high mortality unless
right treatment is instituted at the right time. The ﬁrst step is understanding the mechanism
leading to instability: hemodynamic or ischemic. Right kind of therapy; drugs (ionotropic) or
IABP or other cardiac assist devices should be chosen according to mechanism of insult as
well as degree of insult. Drugs such as ionotropes are effective only in very early course but if
the decompensation has progressed beyond a certain point device such as IABP may be
effective but again only early in the course when CPO? 0.6. Beyond a certain point, even IABP
may not be effective: here only Impella (2.5, CP or 5) or Tandem Heart may be effective.
However, beyond a certain point CPO < 0.53, even these devices may not be effective. Thus
crux of the matter is choice of a right device/drug and timing of its institution.
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Acute decompensated heart failure represents a heteroge-
neous group of the cardiac conditions with some of the worst
acute outcomes among all medical conditions. The etiology
ranges from idiopathic pump failure, to mechanical causes,
ischemic etiology or during the course of high-risk PCI (Table 1).
The reason for decompensation originates either in sudden
hemodynamic compromise or ischemic damage but in most
cases there is a simultaneous occurrence of both ischemic
damage and hemodynamic compromise. However, the rela-
tive contribution of these two mechanisms may differ in
different conditions. While ischemic damage is most impor-
tant contributor in high-risk PCI, and acute coronary syn-
dromes; NSTEMI, STEMI and cardiogenic shock, hemodynamic
compromise is the most important contributor in other types
of decompensations. In any case, it is a vicious cycle: one
leading to another (Fig. 1). The underlying mechanism
contributing to decompensation is very important to recog-
nize, because treatment depends on ability to address the
relevant mechanism.2. Mechanism of destabilization
There are two mechanisms of destabilization: ischemic
damage and hemodynamic compromise.
2.1. Ischemic damage
Reduced oxygen delivery to the heart is essentially a question
of ‘‘demand supply mismatch’’. In other words ischemic
damage happens when the coronaries are unable to deliver
enough blood as required by the myocardium. Thus this
mismatch can happen in two ways (Table 2):
1. Inadequate oxygen delivery: (i) Reduced coronary blood
ﬂow due to atherosclerosis, plaque rupture, and thrombotic
occlusion or any other cause leading to compromise of
blood ﬂow. Technically it is calculated as the difference
between diastolic (mean) coronary arterial BP  LVEDP.
Thus not only reduced blood ﬂow but even raise in LVEDP
can cause a situation of inadequate oxygen delivery. (ii)
Direct inadequacy of oxygen delivery in situations like
Table 1 – Etiology of advanced decompensated heart
failure.
1. Idiopathic
2. Pump failure: myocarditis, hypertension, alumunium phosphide
poisoning
3. Mechanical complications: valve stenosis and regurgitations
4. Ischemic: NSTEMI, STEMI, cardiogenic shock
5. High-risk PCI
Fig. 1 – The course of hemodynamic compromise.
Table 3 – Modalities to decrease the ischemic damage.
How to reduce ischemic insult
Increase oxygen delivery Reduce myocardial
oxygen demand
 Improve coronary blood
ﬂow (difference between
diastolic coronary arterial
BP  LVEDP)
 Decrease heart rate
 Deliver oxygen directly  Decrease contractility
 Administer food products  Reduce preload
 Reduce afterload
 Reduce muscle mass
 Shift pressure volume
area (PVA) curve to right
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worsen this process.
2. Increased myocardial oxygen demand: Increased heart
rate, contractility, preload, after-load and muscle mass can
all increase the oxygen consumption. However, the most
important co-relate of myocardial oxygen demand is
pressure volume area (PVA). A shift of this curve to right
increases the oxygen demand and destabilizes, whereas a
shift to left reduces it. Thus any cardio-protective mecha-
nism, be it drugs or mechanical assist devices, essentially
shifts this curve to left. Paradoxically, ionotropes and other
stimulants (although they increase mean blood pressure
(MBP) initially) push this curve to right. The various
mechanisms to decrease ischemic insult and push the
curve to left are given in Table 3.Table 2 – Mechanism of decompensation.
Mechanism of decompensation
Ischemic damage Hemo-dynamic compromise
 Poor oxygen delivery
Reduced coronary blood
ﬂow: difference between
diastolic (mean) coronary
arterial BP  LVEDP
 Cardiac power
product = CO  MBP/451
 Increased myocardial
oxygen demand
 CPO is direct co-relate of
end-organ perfusion2.2. Hemodynamic compromise
This is the second and more obvious mechanism of destabili-
zation manifest as not only symptoms such as weakness,
sweating and even collapse but also drastic fall in BP. It
correlates with both forward delivery of blood as well as
pressure head. Technically, it is measured as cardiac power
output (CPO), which is derived from the equation:
CPO ¼ CO  MBP=451
A value <0.6 is indicative of hemodynamic compromise,
whereas a value <0.53 is incompatible with life. As can be
seen, there is a very small ‘‘window of opportunity’’, once
hemodynamic compromise starts, and the management has
to be instituted rather quickly and effectively.
3. Management of ischemic and
hemodynamic support
Be it initial ischemic damage or hemodynamic compromise,
the decompensation ensues with fall in CPO < 1. For a very
short duration of time, when the CPO hovers around 1, the
patient may be beﬁtted by use of drugs, which increase the
cardiac output (milrinone/amrinone or levosimendan) or
increase systemic MBP (intravenous ionotropes). However,
very soon this window of opportunity passes away and the use
of these drugs may actually become counter-productive
(Fig. 2).
3.1. Drugs improving cardiac output
Milrinone/amrinone and levosimendan act by increasing the
cardiac output (or at least by preventing a fall in CO)
predominantly by reducing the after-load.1 However, these
drugs paradoxically worsen the energy balance of the heart, by
increasing the oxygen consumption; milrinone more than
levosimendan.2 Thus the overall beneﬁt of this strategy is very
small and that too very early in the course of decompensation.
Further, when ischemic damage is the initial etiology (by
worsening the energy kinetics) these drugs may not beneﬁt at
all.
Fig. 2 – Timing of strategies providing hemodynamic
support.
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The major mechanism of effectiveness of these drugs is by
elevation of BP (MBP) but the other component of CPO i.e.
cardiac output is not affected much (as there is no increase in
stroke volume), and so overall CPO is only marginally elevated.
On the other hand, "LVEDP caused by these drugs worsens
ischemia and thus the balance of action is that on short term
they may transiently stabilize hemodynamics at the cost of
worsening ischemia, but with long-term deleterious effects.
Further, this therapy may be associated with complications,
including arrhythmia, worsening ischemia, etc. Understand-
ably, when the cause of decompensation is ischemic, these
drugs are practically useless.
3.2.1. Role of IABP
In situations, where ischemic mechanism is more important
than hemodynamic e.g. high risk PCI hemodynamic compro-
mise follows the ischemic insult but starts the vicious cycle
causing more ischemic insult (because of decreased coronary
perfusion). Here stabilization of ischemia is more important, or
in other words, techniques, which increase myocardial oxygen
delivery or reduce its requirements, are mandatory. IABP is
one such a device. Here the mechanism of stabilization is
indirect LV unloading and consequent reduction in LVEDP and
augmentation of stroke volume (and therefore CO) and
elevation of MBP. Improved coronary energetic is as a
consequence of increased coronary delivery: increased dia-
stolic coronary pressure (as a consequence of increased MBP)
and reduced LVEDP. The effect on hemodynamics is also
salutary: increased MBP and increased CO (CPO improves by
10%). Finally, as a result of unloading of LV, the oxygen
requirement of heart also decreases by shifting the PVA curve
slightly to left. Thus the effect of IABP is beneﬁcial but modest.
Further as shown in Fig. 2 the window of opportunity is small,
before CPO reaches 0.6. Thus the timing is critical. A study by
Mishra and co-workers has actually shown that once the
destabilization  becomes manifest very little can be done. On
the other hand there is a role of prophylactic ally supporting with
IABP in high risk situations.3 The bottom line is that to be
effective, the degree of support both ischemic and hemodynamicshould co-relate with degree of insult and device chosen within
appropriate time.4,5
3.2.2. Tandem heart
The main mechanism of beneﬁcial action is indirect LV
unloading (connecting left atrium to common iliac artery) and
the effect predominantly hemodynamic: increased MBP and
increased CO (4 L/min) so that overall CPO improves by 80%.
There is some ischemic beneﬁt as well, which operates via
indirectly unloading LV (and so reducing LVEDP). However,
during shock, there is a paradoxical worsening of ischemia due
to increasing oxygen requirement because of shifting of the
PVA curve to the right. Further, there are several issues with
this device: technical – the implantation technique is very
complex and involves obtaining double access and trans-
septal puncture (21F venous for LA and 15F arterial). It takes at
least 30 min for implantation. Further, the risk of limb
ischemia is the highest among all and so is the bleeding risk
and requirement of transfusion. In addition, there is risk of
residual ASD. It is contra-indicated in VSD, peripheral vascular
disease and RV Failure. The magnitude of hemodynamic
beneﬁt is good, but it may worsen ischemia in shock. This
device is effective, when the CPO is >0.53 (Fig. 2).
3.2.3. Impella device
Here, the mechanism of action is by direct unloading of LV into
aorta and as a consequence, providing huge hemodynamic
support – increased MpP and increased CO (2.5 L/min with
Impella 2.5 and 5 L/min with Impella 5), which leads to CPO
improvement of 50% in Impella 2.5 and 100% in Impella 5.
Further, there is ischemic beneﬁt as well again operative via
direct LV unloading, which shifts PVA curve to left even during
shock as also reducing LVEDP. Thus the hemodynamic support
provided is as follows: Impella 2.5 < tandem heart < Impella 5.
The new Impella CP, which can be inserted percutaneously
provides a CO of 4 L/min (like Tandem Heart) but which is
coupled with a good ischemic beneﬁt as well. Here the
communication is between LV ! ascending aorta, which
directly unloads LV (providing ischemic beneﬁt as well). The
technique involves single arterial puncture (Impella 2.5 – 13F,
Impella CP – 14F). The technique is less difﬁcult compared to
Tandem Heart, the ease of implantation intermediate and it
takes about 10 min for percutaneous procedure. The implan-
tation carries a moderate risk of limb ischemia but a minimal
risk of bleeding and requirement of transfusion. Its use is
contra-indicated in presence of LV thrombus, VSD, severe AS
and RV failure. Thus the only problem with this device is
requirement of relatively large arterial access.6,7 This device is
also effective when the CPO is >0.53 (Fig. 2).
3.2.4. ECMO
It is essentially a mini-cardiopulmonary bypass. It involves
right atrial–aorta connection and leads to indirect LV unload-
ing. It is useful in very sick patients.8–10
4. Conclusions
Advanced decompensated heart failure is a heterogenous
condition with a high mortality. It is important to understand
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 1 – s 4S4the etiology, mechanism, and degree of decompensation.
Choice of right strategy drug or device at the right time is
critical in successful outcome.
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